Study of brain signals as signs of Rett syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study measures brain and nerve activity (brain signals) to find patterns that match Rett syndrome. It may help researchers better track Rett changes over time and develop more precise ways to measure response in future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a female with age 3 to 18 and a confirmed MECP2 disease-causing genetic change (for the Rett group)
- Or be a female age 1 to under 5 with an MECP2 disease-causing genetic change, and either no regression yet or regression occurred within the last 6 months
- Or be a female age 1 to 18 with no developmental or thinking concerns (typically developing group)
- For Rett groups: do not have extra MECP2 copies or another known disease-causing gene change
- For Rett groups: no other active medical conditions that are not typical for Rett syndrome
- For typically developing group: have normal test results, no known neurological disorder (except migraine), and not be on brain/nerve (neuroactive) medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures brain waves and hearing in people with Rett syndrome to better understand how the condition affects the brain's ability to process sound. The information may help develop better treatments and support.
This trial tests a new study drug called NTI164 to see if it can safely help manage Rett syndrome symptoms in girls and young women. It is for those with classic Rett syndrome who have been stable recently and are not using certain other treatments.
This study tests new wearable sensors to track symptoms like heart rate and breathing in people with Rett syndrome. If you join, you'll use the sensors at home to help researchers see how symptoms change day to day.
This trial tests an oral medication called NA-921 in females with Rett syndrome to see if it works better than a placebo. It may be an option for those who have a confirmed MECP2 gene mutation and stable seizure patterns.
This trial is a registry that collects health and genetic information from people with Rett syndrome. It may help researchers better understand how MECP2 loss-of-function changes lead to symptoms and how to support patients.
This trial tests a gene-editing approach for Rett syndrome in children who have a confirmed MECP2 gene mutation. It may help by targeting specific “hotspot” genetic changes that cause the condition.
Hear when a new Rett Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.